Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting

Journal of Neuro-Oncology

Volumn 130, Issue 1, 2016, Pages 53-62

  Munthe, Sune ^a,b   Sørensen, Mia D ^a,b   Thomassen, Mads ^a,b   Burton, Mark ^a,b   Kruse, Torben A ^a,b   Lathia, Justin D ^c,d   Poulsen, Frantz Rom ^a,b   Kristensen, Bjarne Winther ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer stem cell; Glioblastoma; Invasion; Migration

Indexed keywords

ALPHA6 INTEGRIN; BMI1 PROTEIN; CD133 ANTIGEN; CD15 ANTIGEN; CD36 ANTIGEN; CELL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; PODOPLANIN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; HOMEODOMAIN PROTEIN; TRANSCRIPTION FACTOR SOX;

ARTICLE; CANCER STEM CELL; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA CELL; HOX GENE; HUMAN; HUMAN CELL; PHENOTYPE; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; KAPLAN MEIER METHOD; METABOLISM; MICROARRAY ANALYSIS; MORTALITY; MOUSE; MULTICELLULAR SPHEROID; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; SERUM-FREE MEDIUM; TIME FACTOR; TUMOR CELL LINE; XENOGRAFT;

AC133 ANTIGEN; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA, SERUM-FREE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE; MICROARRAY ANALYSIS; NEOPLASTIC STEM CELLS; RNA, MESSENGER; SOXB1 TRANSCRIPTION FACTORS; SPHEROIDS, CELLULAR; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84981186237     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2221-y     Document Type: Article

References (32)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J of Med 352(10):987–996. doi:10.1056/NEJMoa043330
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. lancet Oncol 10(5):459–466. doi:10.1016/s1470-2045(09)70025-7
3. Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39(2):235–250
4. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217. doi:10.1101/gad.261982.115
5. Albini A, Bruno A, Gallo C, Pajardi G, Noonan DM, Dallaglio K (2015) Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res 56:414–425. doi:10.3109/03008207.2015.1066780
6. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nature Rev Cancer 5(4):275–284 doi:10.1038/nrc1590
7. Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S (2010) Cancer stem cells in glioblastoma–molecular signaling and therapeutic targeting. Protein Cell 1(7):638–655. doi:10.1007/s13238-010-0078-y
8. Munthe S, Petterson SA, Dahlrot RH, Poulsen FR, Hansen S, Kristensen BW (2016) Glioma cells in the tumor periphery have a stem cell phenotype. PloS One 11(5):e0155106. doi:10.1371/journal.pone.0155106
9. Rodriguez LG, Wu X, Guan JL (2005) Wound-healing assay. Methods Mol Biol 294:23–29
10. Boyden S (1962) The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115:453–466
11. Kramer N, Walzl A, Unger C, Rosner M, Krupitza G, Hengstschlager M et al (2013) In vitro cell migration and invasion assays. Mut Res 752(1):10–24. doi:10.1016/j.mrrev.2012.08.001
12. Guan J-L (2005) Cell migration: developmental methods and protocols. Humana Press, Totowa, p 364
13. Tosh D, Slack JM (2002) How cells change their phenotype Nat Rev Mol cell Biol 3(3):187–194. doi:10.1038/nrm761
14. Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W et al (2009) Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 279(1):13–21. doi:10.1016/j.canlet.2009.01.016
15. Brehar FM, Bleotu C, Stefan LM, Buzgariu W, Chivu M, Utoiu E et al (2009) Isolation and partial characterization of a new human glioblastoma cell line. Chirurgia (Bucur) 104(4):453–461
16. Jensen SS, Aaberg-Jessen C, Andersen C, Schroder HD, Kristensen BW (2013) Glioma spheroids obtained via ultrasonic aspiration are viable and express stem cell markers: a new tissue resource for glioma research. Neurosurgery 73(5):868–886 (discussion 86). doi:10.1227/neu.0000000000000118
17. Halle B, Thisgaard H, Hvidsten S, Dam JH, Aaberg-Jessen C, Thykjaer AS et al (2015) Estimation of tumor volumes by [11C] MeAIB and [18F] FDG PET in an orthotopic glioblastoma rat model. J Nucl Med. doi:10.2967/jnumed.115.162511
18. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N et al (2011) Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J NeuroOncol 103(1):43–58. doi:10.1007/s11060-010-0357-8
19. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110. doi:10.1016/j.ccr.2009.12.020
20. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828
21. Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D (1999) Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev Biol 208(1):166–188. doi:10.1006/dbio.1998.9192
22. Hu Y, Smyth GK (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347:70–78
23. Jensen SS (2013) Novel models and therapeutic strategies in glioblastoma. PhD Thesis, University of Southern Denmark
24. Pecaric J, Varosanec S (2001) Simpson’s formula for functions whose derivatives belong to L-p spaces. Appl Math Lett 14(2):131–135. doi:10.1016/S0893-9659(00)00124-5
25. http://www.bioconductor.org/packages/release/bioc/html/limma.html. Accessed Sept 2015
26. Piccirillo SG, Dietz S, Madhu B, Griffiths J, Price SJ, Collins VP et al (2012) Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer 107(3):462–468. doi:10.1038/bjc.2012.271
27. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A et al (2008) CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122(4):761–768. doi:10.1002/ijc.23130
28. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer cell 15(6):501–513. doi:10.1016/j.ccr.2009.03.018
29. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20):3274–3284
30. Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I et al (2015) Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biol 16:16. doi:10.1186/s13059-015-0583-7
31. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437. doi:10.1016/j.ccr.2012.08.024
32. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110(10):4009–4014. doi:10.1073/pnas.1219747110